blood making everyone. look expect the pride patients Thank enthusiasm my globally. available progress in and forward afternoon, treated components in you, to we've colleague's Vivek we the INTERCEPT progress and to more good share and even I made
our XX% by to mentioned product third year-to-date XXXX the of continues Vivek revenues product medicine. in XXXX remarks, sales platelet only shy INTERCEPT position compared at revenue in this transfusion his revenues, Cerus' about US. totaling quarter year year coming record end during dollars million reported a in breakout strong and of representing led third increase full product $XX.X strong in the we demonstrate As of million, quarter, With the the a to QX,
year-over-year growth depicts increase a Moving sequentially. on increase and to which our XX% a calculated as platelet dose globally, XX% calculated
product represented represent the of product total In and sales revenue. QX terms sales of by market of than INTERCEPT XX% growth more Of to steady platelet for in XX% our our that over the of mix US kits market. underpinned kits EMEA product quarter, continue the
our to In our revenues not quarter third guidance, addition contract included government XXXX. revenue, of totaled the product totaled Comparatively, revenue in QX. in $X.X contract million million in $X and government
FDA. the revenue a clinical trials, blood stated our cell for blood comprised reduction have we contract funded to primarily previously, by is whole contract and, red extent As government reimbursement BARDA of lesser pathogen
As the under patient on effort government contract we rail, whole and activity to BARDA blood expect enrollment revenue trials increase. the
we we portion as later, offset the year, Additionally, next little an revenues a the revenue that expense gross of margins. R&D to spend. But out contract turn essentially in this product of for measure core our will metric gross business since an is being, Beginning discuss aside, are time both offsetting EBITDA effort plan highlight using that government to and strip let's we and to core a activities. line to adjusted to business progress the our profit
compared was prior the period XX.X% driven profit Product profit gross compared period. gross by to our XXXX year gross year company's flat product the margins million, in history $XX.X primarily for gross quarter product the increase were higher compared $XX.X to during highest margins. the million The the were when was at Third prior to sales. quarter XX.X% QX and for in roughly
kids prior anticipated during product and predominantly of first year-over-year the selling with the associated half volume our gross year Today, use now percentage operating lower which we third will platelet double case period. as expenses, customers like decline driven kits, non-cash product and million forecast, the expect margin dose we number the dose a to single the by that a included of dose year, unfavorable $XX.X Over was was stock totaled higher in As single the primarily contribution market market the our than in an the US in mix and US during margin I dose increased discuss kits. kits. time, platelet carry $X.X based compensation. use million quarter our double which of versus
instead driven year-over-year about Of demonstrate up $X to strong the to versus leverage $XX.X the increased $XX.X expenses operating quarter on operating expenses of by million sales. year of expenses in business associated third for the quarter accounted expenses, approximately prior were the during sales we compared was expenses to with SG&A compared with prior million the our period. QX During year year. Research totaled compensation. million for operating total only SG&A by Development prior the our XX% The continued costs $XX.X and million, increase total and product higher the
During compensation costs. of cell red efforts, the quarter, including US and we along with blood pipeline continued illuminator to stock based LED advance the a projects, variety increased our
However, and lower with realized passed and offsetting being IFC, the R&D investments now study these costs we such development projects commercialized. in rolling certain programs, mature PIPER as has our of which associated
achieving billion reported On to the million, or attributable net the Net the pivotal diluted $XX.X for in for on breakeven, cash September $X.XX short diluted $X.XX and for business XXXX. the share three loss With XXXX, improved long-term. continuing path when bottom leverage totaled in operating to focused to line, per attributable invest per during this QX for months prior in while to Cerus Cerus loss the respect both share, period. to $XX.X towards driving ended same to growth remained we've year flow compared year the period compared or XX, our
this forward, using namely XXXX. the in in income, beginning a we progress our core amortization To to or pro well such will business below such non-core while our help expense metric stock a operating for Essentially earnings towards income, other highlight more EBITDA. moving adjusting non-cash operating flow income items us revenue, color government corresponding depreciation, and we subsequent As forma cash on provide our and calling measure costs as calls, taxes. adjusted breakeven business plan are compensation, loss items remains track the our income this as contract as as and based line activities, priority
the strong in approximately continued of In $XXX terms with a of reflects sequential for Cash cash the equivalents million, course hand. and quarter over a the operations $X.X was investments million our balance quarter sheet, XXXX. from used on we ended short-term improvement position third which cash, of
expanding demand committed platelets to customers for INTERCEPT robust debt see to supply without to from access blood allow our ability remain ensure continue customers, ability role and important business their we to the support play line revolving our facility of resources. in deploy continue to end, that to we As our our to and the depleting credit invest continuing and an to us To will growth supply. of to cash the
visibility XXX guidance year revenue coupled the year-to-date, out revenue XXXX. of on into range million have The million Obi to XXXX. to the compared in of we the strength the narrowing prior when turn to business let me going range for of With and have million. to us that, XXX call range reflects Moving XX% comments. growth resulted product year balance to to round XX% product our million XXX from also to some XXX with the increasing full our guidance new to over back closing This
